Anabela Cardoso

1 week ago | dermatologytimes.com | Anabela Cardoso |Kaitlyn Bader

At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, Eli Lilly and Company presented new data from the phase 3b ADmirable trial (NCT05372419) of lebrikizumab (Ebglyss).1 The study is the first to evaluate lebrikizumab’s effectiveness and safety in adult and adolescent patients with pigmented skin and atopic dermatitis, as this population is typically underrepresented in clinical trials.

Mar 11, 2025 | dermatologytimes.com | Kaitlyn Bader |Anabela Cardoso

“With lebrikizumab, in addition to showing fast initial relief of each and skin, which we showed at 16 weeks, we now looked at the patients who achieved that, and what are the outcomes after 3 years.

Mar 9, 2025 | dermatologytimes.com | Kaitlyn Bader |Anabela Cardoso

“This study we presented here for the first time is just dedicated to adolescents. It is the largest study of a JAK inhibitor dedicated to adolescents with severe alopecia areata,” said Anabela Cardoso, MD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.